Results 1 to 10 of about 24,454,690 (224)

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia [PDF]

Clinical Pharmacology: Advances and Applications, 2022
Constantine E Kosmas,1,2 Maria D Bousvarou,3 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,2 Rogers Echavarria Uceta,2 Eliscer Guzman1,2 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA ...
Kosmas CE, Bousvarou MD, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E   +6 more
doaj   +5 more sources

Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia. [PDF]

Int J Mol Sci, 2021
Dyslipidemia is characterized by increasing plasma levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TGs) and TG-rich lipoproteins (TGRLs) and is a major risk factor for the development of atherosclerotic cardiovascular disorders (ASCVDs).
Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH.   +5 more
europepmc   +6 more sources

Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children [PDF]

Frontiers in Pediatrics, 2023
BackgroundAngiopoietin-like 3 (ANGPTL3) is a secretory glycoprotein. It has been demonstrated that ANGPTL3 level was upregulated in minimal change nephrotic syndrome (MCNS) kidney tissues.
Fujie Wen, Junchao Liu, Rufeng Dai, Sha Hong, Baowei Ji, Jiaojiao Liu, Jun Zhang, Xinli Han, Qianying Lv, Jialu Liu, Qian Shen, Hong Xu   +11 more
doaj   +4 more sources

Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria [PDF]

Lipids in Health and Disease, 2019
Background Angiopoietin-like protein 3(ANGPTL3) is well acknowledged as a key regulator of lipid metabolism. Now, there have not been enough data to explain the mechanism of hyperlipidemia related proteinuria.
Xia Gao, Yanhong Suo, Min Zhang, Yan Wang, Xin Gao, Qiu Bing, Qingju Liu   +6 more
doaj   +5 more sources

Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism1[S] [PDF]

Journal of Lipid Research, 2016
The consequences of angiopoietin-like protein 3 (ANGPTL3) deficiency on postprandial lipid and lipoprotein metabolism has not been investigated in humans.
Ilenia Minicocci, Anna Tikka, Eleonora Poggiogalle, Jari Metso, Anna Montali, Fabrizio Ceci, Giancarlo Labbadia, Mario Fontana, Alessia Di Costanzo, Marianna Maranghi, Aldo Rosano, Christian Ehnholm, Lorenzo Maria Donini, Matti Jauhiainen, Marcello Arca   +14 more
doaj   +6 more sources

Regulation of the angiopoietin-like protein 3 gene by LXR [PDF]

Journal of Lipid Research, 2003
Angiopoietins are members of the vascular endothelial growth factor family. One family member, angiopoietin-like protein 3 (Angpt1111111175), was recently shown to be predominantly expressed in the liver and to play an important role in regulating lipid ...
Rebecca Kaplan, Theresa Zhang, Melba Hernandez, Frank Xiaodong Gan, Samuel D. Wright, M.Gerard Waters, Tian-Quan Cai   +6 more
doaj   +3 more sources

Serum Angiopoietin-like Protein 3 Levels Are Associated with Endothelial Function in Patients with Maintenance Hemodialysis [PDF]

Life, 2023
Angiopoietin-like protein 3 (ANGPTL3) plays an important role in lipid and lipoprotein trafficking and metabolism and is positively correlated with cardiovascular disease.
Tzu-Chiang Wu, Bang-Gee Hsu, Chiu-Huang Kuo, Chih-Hsien Wang, Jen-Pi Tsai   +4 more
doaj   +2 more sources

Positive correlation of serum angiopoietin-like protein 3 levels with metabolic syndrome in patients with coronary artery disease [PDF]

Tzu Chi Medical Journal, 2022
Objectives: Angiopoietin-like protein 3 (ANGPTL3) regulates triglyceride metabolism by reversibly inhibiting the lipoprotein lipase activity. Metabolic syndrome (MetS) is an independent risk factor for further cardiovascular disease. This study evaluated
Sy-Harn Lian, Bang-Gee Hsu, Ji-Hung Wang, Ming-Chun Chen   +3 more
doaj   +2 more sources

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice [PDF]

Journal of Lipid Research, 2021
Supported by an abundance of experimental and genetic evidence, angiopoietin-like protein 3 (ANGPTL3) has emerged as a promising therapeutic target for cardiovascular disease. ANGPTL3 is primarily produced by the liver and is a potent modulator of plasma
Thomas A. Bell, III, Mingxia Liu, Aaron J. Donner, Richard G. Lee, Adam E. Mullick, Rosanne M. Crooke   +5 more
doaj   +2 more sources

Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias. [PDF]

Int J Mol Sci
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality, despite advances in pharmacological prevention and treatment. The burden of CVD necessitates implementing the treatment of risk factors including dyslipidemia. Pharmaceutical advancements and in depth understanding of pathophysiology have enabled innovative therapies ...
Kosmas CE, Rallidis LS, Hoursalas I, Papakonstantinou EJ, Kostara CE.   +4 more
europepmc   +3 more sources